Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.71 |
| ▸ | DRD2 | P14416 | 3/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852363 | 0.89 | SIGMAR1 (0.70) | HTR2ADRD2SIGMAR1ADRA1DADRA1A | |
| SCHEMBL19852225 | 0.84 | HTR2A (1.00) | HTR2ADRD2SIGMAR1ADRA1DADRA1A | |
| SCHEMBL19852226 | 0.79 | ADRA1D (0.67) | HTR2ADRD2SIGMAR1ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL11545618 | 0.78 | DRD2 (0.60) | HTR2ADRD2SIGMAR1HRH3KCNH2 | |
| SCHEMBL8010281 | 0.76 | DRD2 (0.74) | HTR2ADRD2SIGMAR1ADRA1DADRA1A | |
| SCHEMBL7439064 | 0.76 | DRD2 (0.83) | HTR2ADRD2SIGMAR1ADRA1DADRA1A | |
| SCHEMBL10669091 | 0.74 | HRH3 (1.00) | SIGMAR1HRH3HTR1ASLC6A4 | |
| SCHEMBL8506973 | 0.74 | ABCB1 (0.71) | SIGMAR1ADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL17319036 | 0.74 | SIGMAR1 (0.57) | SIGMAR1ADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL11254741 | 0.74 | DRD2 (0.80) | HTR2ADRD2SIGMAR1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | HTR2A 2/4885DRD2 69/4885SIGMAR1 612/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | HTR2A 2/4885DRD2 69/4885SIGMAR1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.